Malignant disease and immunosuppression

▼Fingolimod for multiple sclerosis
Drug and Therapeutics Bulletin Feb 2012, 50 (2) 18-20; DOI: 10.1136/dtb.2012.02.0086
Adrenaline for anaphylaxis
Drug and Therapeutics Bulletin Mar 1994, 32 (3) 19-21; DOI: 10.1136/dtb.1994.32319
TNF antagonists for ankylosing spondylitis
Drug and Therapeutics Bulletin Mar 2005, 43 (3) 19-22; DOI: 10.1136/dtb.2005.43319
Oral or intramuscular vitamin B₁₂?
Drug and Therapeutics Bulletin Feb 2009, 47 (2) 19-21; DOI: 10.1136/dtb.2009.01.0002
Herbal medicines for menopausal symptoms
Drug and Therapeutics Bulletin Jan 2009, 47 (1) 2-6; DOI: 10.1136/dtb.2008.12.0031
Tinnitus
Drug and Therapeutics Bulletin Feb 2013, 51 (2) 20-24; DOI: 10.1136/dtb.2013.1.0162
Systemic lupus erythematosus
Drug and Therapeutics Bulletin Mar 1996, 34 (3) 20-23; DOI: 10.1136/dtb.1996.34320
Buprenorphine for opioid dependence
Drug and Therapeutics Bulletin Mar 2007, 45 (3) 20-24; DOI: 10.1136/dtb.2007.45320
Endpoints in asthma drug trials - what do they mean?
Drug and Therapeutics Bulletin Mar 2006, 44 (3) 21-24; DOI: 10.1136/dtb.2006.44321
Epoetins and ▼darbepoetin alfa in malignant disease
Drug and Therapeutics Bulletin Mar 2004, 42 (3) 21-24; DOI: 10.1136/dtb.2004.42321

Main menu